Search | IOVS | ARVO Journals

View

Showing 1 – 13 of 13

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

OCT

K.D. Rosenberg; H.W. Flynn, Jr.; I.U. Scott; A.A. Moshfeghi

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5275. doi:

ARVO Annual Meeting Abstract May 2005

Optical Coherence Tomography (OCT) Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

C.A. Puliafito; P.J. Rosenfeld; S. Michels; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1376. doi:

ARVO Annual Meeting Abstract May 2005

Indocyanine Green Angiographic Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

K.D. Rosenberg; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; A.E. Fung

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1377. doi:

ARVO Annual Meeting Abstract May 2005

Safety of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

S.M. Michels; P.J. Rosenfeld; C.A. Puliafito; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1378. doi:

ARVO Annual Meeting Abstract May 2005

Durability of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

A.A. Moshfeghi; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.E. Fung; K.D. Rosenberg; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1381. doi:

ARVO Annual Meeting Abstract May 2005

Fluorescein Angiographic Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

A.E. Fung; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1382. doi:

ARVO Annual Meeting Abstract May 2005

Posterior Juxtascleral Injection of Anecortave Acetate: Localization in Rabbit Eyes by Magnetic Resonance and Ecographic Imaging

M.E. Jockovich; A.A. Moshfeghi; E. Hernandez; P.D. Clifford; T.G. Murray

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):482. doi:

ARVO Annual Meeting Abstract May 2005

Non–infectious Pseudohypopyon Following Intravitreal Triamcinolone Acetonide (IVTA) Injection

H.W. Flynn; A.A. Moshfeghi; J.L. Davis; J.W. Kitchens; T.G. Murray; C.A. Puliafito; P.J. Rosenfeld; I.U. Scott; W.E. Smiddy

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):486. doi:

ARVO Annual Meeting Abstract May 2005

Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration (SANA) Study: Visual Acuity Outcomes

P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2310. doi:

ARVO Annual Meeting Abstract May 2004

Pseudohypopyon Following Intravitreal Triamcinolone Acetonide Injection for Cystoid Macular Edema

H.W. Flynn; Jr; A.A. Moshfeghi; I.U. Scott; C.A. Puliafito

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):1046. doi:

ARVO Annual Meeting Abstract May 2004

Verteporfin Therapy with Intravitreal Triamcinolone in Patients with Neovascular AMD

A.A. Moshfeghi; C.A. Puliafito; P.J. Rosenfeld

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3159. doi:

ARVO Annual Meeting Abstract May 2003

Lens-sparing Vitrectomy for Tractional Stage 4A Retinopathy of Prematurity Retinal Detachments

A.A. Moshfeghi; M.J. Banach; G.A. Salam; P.J. Ferrone

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):604. doi:

ARVO Annual Meeting Abstract May 2003

Intravitreal Triamcinolone Acetonide Injection for Diabetic Macular Edema: Effect of Preparation Technique on Incidence of Anterior Chamber Reaction

G.A. Salam; A.A. Moshfeghi; D.M. Fastenberg; V.A. Deramo; P.J. Ferrone

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):4013. doi:

Advertisement